E. Sicart

A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

J. Tabernero, C. Michie, C. Kahatt, 2013, Cancer Chemotherapy and Pharmacology.

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

J. Seoane, I. Braña, M. Mitchell, 2016, Drugs in context.

Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY).

J. Baselga, J. Seoane, M. Carducci, 2013 .

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

J. Baselga, J. Seoane, M. Carducci, 2014, Clinical Cancer Research.

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

J. Baselga, J. Seoane, M. Carducci, 2014, Investigational New Drugs.

First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.

J. Baselga, J. Seoane, M. Carducci, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

J. Baselga, J. Seoane, L. Paz-Ares, 2014, Clinical Cancer Research.

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

J. Seoane, I. Braña, M. Mitchell, 2016, Drugs in context.